Mr.steve Engle
Non-Executive Chairman
Prescient Therapeutics
Australia
Biography
Steve Engle is CEO of Averigon Consulting, an advisory firm to the life science industry. Previously, Mr Engle was Chairman and CEO of XOMA, a developer of antibody therapeutics for inflammatory, metabolic and other diseases. Prior to that, he was Chairman and CEO of La Jolla Pharmaceutical Company, which discovered the biology of B cell tolerance, developed the first B cell toleragen for lupus patients, and received an approvable letter from the FDA. Mr Engle served as VP of Marketing for Cygnus, a drug delivery company, where he helped gain FDA approval of and launch Nicotrol for smoking cessation. He was VP of Marketing at a $50 million device company and a management consultant at Strategic Decisions Group and SRI (Stanford Research Institute) International. Mr Engle is a Board member of Anthera Pharmaceuticals with clinical stage products in lupus and enzyme replacement, Prescient Therapeutics (ASX: PTX) with clinical stage oncology products, and AROA Biosurgery, a privately held developer of regenerative medicine products. Mr Engle is a former Board member of BIO, Baybio, BIOCOM and the Lupus Foundation of America. Mr Engle holds a B.S. and an M.S. in electrical engineering with a focus in biomedical engineering from the University of Texas at Austin.
Research Interest
Research interest on Business development
